Special Issues
Table of Content

Immunotherapy in Early-Stage and Locally Advanced Resectable Non-small Cell Lung Cancer

Submission Deadline: 30 June 2026 (closed) View: 598 Submit to Special Issue

Guest Editor(s)

Prof. Francesco Petrella

Email: francesco.petrella@irccs-sangerardo.it; francesco.petrella@unimi.it

Affiliation: Department of Thoracic Surgery, Fondazione IRCCS San Gerardo dei Tintori, Monza, 20900, Italy; Department of Oncology and Hemato-oncology, Univeristy of Milan, Milan, 20122, Italy.

Homepage: www.francescopetrella.com

Research Interests: Lung cancer, mesothelioma, pulmonary metastasectomy, chest wall tumors, mediastinal tumors

图片2.png


Summary

The integration of immunotherapy into the management of early-stage and locally advanced resectable non-small cell lung cancer (NSCLC) is transforming the therapeutic landscape. While surgery remains the cornerstone of curative treatment, recurrence rates after resection remain high, particularly in patients with stage II–III disease. Recent advances in immune checkpoint inhibitors (ICIs), targeting PD-1/PD-L1 pathways, have demonstrated significant improvements in both event-free survival and overall survival when used in neoadjuvant or adjuvant settings. Landmark trials have shown that neoadjuvant chemo-immunotherapy can increase pathological complete response rates without compromising surgical feasibility. Similarly, adjuvant immunotherapy has prolonged disease-free survival in high-risk patients following complete resection and platinum-based chemotherapy.

These findings suggest that perioperative immunotherapy may alter the natural history of resectable NSCLC, providing durable immune-mediated tumor control and reducing recurrence risk. However, several challenges remain, including optimal patient selection, biomarkers for response prediction, treatment sequencing, and management of immune-related toxicities. This special issue aims to highlight current evidence, ongoing trials, and future directions in the use of immunotherapy for early-stage and locally advanced resectable NSCLC, emphasizing its growing role as part of a multimodal, personalized treatment strategy.


Keywords

secondary lung cancer, non-small cell lung cancer (NSCLC), pulmonary metastasectomy, immunotherapy

Published Papers


  • Open Access

    REVIEW

    Immune Mechanisms and Stem Cells in Early-Stage Non-Small Cell Lung Cancer: A Systematic Review

    Aleksandra Litkowska, Anna Grenda, Paweł Krawczyk
    Oncology Research, DOI:10.32604/or.2026.082451
    (This article belongs to the Special Issue: Immunotherapy in Early-Stage and Locally Advanced Resectable Non-small Cell Lung Cancer)
    Abstract Objectives: Early-stage non-small cell lung cancer (NSCLC) may represent a period during which interactions between emerging tumor cells and the immune system influence subsequent disease progression. This systematic review aimed to summarize current evidence on immune dynamics, tumor microenvironment (TME) remodeling, immune evasion mechanisms, and the potential implications of these processes for early therapeutic intervention. Methods: A systematic literature search was conducted in PubMed, Scopus, and Google Scholar for studies published between 1998 and 2026. Original articles, reviews, experimental studies, and clinical trials published in English were included if they addressed tumor immunology, the TME,… More >

  • Open Access

    REVIEW

    The Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer

    Francesco Petrella, Andrea Cara, Enrico Mario Cassina, Lidia Libretti, Emanuele Pirondini, Federico Raveglia, Maria Chiara Sibilia, Antonio Tuoro
    Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.076281
    (This article belongs to the Special Issue: Immunotherapy in Early-Stage and Locally Advanced Resectable Non-small Cell Lung Cancer)
    Abstract The advent of immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 has transformed the therapeutic landscape of advanced non-small cell lung cancer (NSCLC), and recent clinical trials have extended their application to resectable disease. Multiple randomized phase III trials have demonstrated that neoadjuvant and adjuvant immunotherapy, particularly when combined with platinum-based chemotherapy, significantly improves pathological complete response (pCR), major pathological response (MPR), event-free survival (EFS), disease-free survival (DFS), and overall survival (OS) compared to chemotherapy alone. Several key questions remain unresolved—including whether preoperative or postoperative immunotherapy yields superior outcomes, whether adjuvant therapy provides additional More >

Share Link